[1] Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391): 1145-1147.
[2] Shamlott MJ, Axelwan J, Wang S. Derivation of pluripotent stem cell from ultured human primordial germ cell. Proc Natl Acad Sci USA. 1998;95: 13726-13731.
[3] Lin T, Chao C, Saito S, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biolo. 2004;7(2): 165-171.
[4] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4): 663-676.
[5] Laywell ED, Rakic P, Kukekov VG, et al. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci U S A. 2000;97(25): 13883-13888.
[6] http://stemcells.nih.gov/info/pages/glossary.aspx
[7] Thomson JA, Kalishman J, Golos TG, et al. Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A. 1995;92(17):7844-7848.
[8] Keller GM. In vitro differentiation of embryonic stem cells. Curr Opin Cell Biol. 1995;7(6):862-869.
[9] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858): 1917-1920.
[10] Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4(5): 381.
[11] Illmensee K, Hoppe PC. Nuclear transplantation in Mus musculus: developmental potential of nuclei from preimplantation embryos. Cell. 1981;23(1): 9-18.
[12] McGrath J, Solter D. Nuclear transplantation in the mouse embryo by microsurgery and cell fusion. Science. 1983; 220(4603): 1300-1302.
[13] Campbell KHS, McWhir J, Ritchie WA, et al. Sheep cloned by nuclear transfer from a cultured cell line. Nature. 1996; 380 (6569): 64-66.
[14] McKay R. Stem cells hype and hope. Nature. 2000;406(6794): 361-364.
[15] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.
[16] Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425(6960): 836-841.
[17] Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell. 2004;116(5): 639-648.
[18] Vogel G.. Can adult stem cells suffice. Science. 2001; 292 (5523):1820.
[19] Alison MR, Islam S. Attributes of adult stem cells. J Pathol. 2009;217(2): 144-160.
[20] Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell niche in skin. Science. 2004;303(5656): 359.
[21] Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A. 1992;89(7): 2804-2808.
[22] Gunsilius E, Gastl G, Petzer AL. Hematopoietic stem cells. Biomed Pharmacother. 2001;55(4):186-194.
[23] Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5): 641-650.
[24] Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med. 2001;226(6): 507-520.
[25] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411): 143-147.
[26] Rogers I, Casper RF. Umbilical cord blood stem cells. Best Pract Res Clin Obstet Gynaecol. 2004;18(6):893-908.
[27] Johansson CB, Momma S, Clarke DL, et al. Identification of a neural stem cell in the adult mammalian central nervous system. Cell. 1999;96(1): 25-34.
[28] Kennea NL, Mehmet H. Neural stem cells. J Pathol. 2002; 197(4):536-550.
[29] Redmond DE Jr, Bjugstad KB, Teng YD, et al. Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A. 2007;104(29):12175-12180.
[30] Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders–how to make it work. Nat Med. 2004;10 Suppl:S42-50.
[31] Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439(7072):84-88.
[32] van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009;71:241-60.
[33] Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428(6979):145-150.
[34] Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science. 2000;287 (5457): 1442-1446.
[35] Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification‐an intergroup rhabdomyosarcoma study. Cancer. 1995;76(6):1073-1085.
[36] Logothetis CJ, Samuels ML, Trindade A, et al. The growing teratoma syndrome. Cancer. 1982; 50(8): 1629-1635.
[37] Bomken S, Fišer K, Heidenreich O, et al. Understanding the cancer stem cell. Br J Cancer. 2010;103(4):439-445.
[38] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859): 105-111.
[39] Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19): 9339-9344.
[40] Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34): 4741-4751.
[41] Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003; 423(6937): 255-260.
[42] Ju Z, Rudolph KL. Telomeres and telomerase in cancer stem cells. Eur J Cancer. 2006;42(9):1197-1203.
[43] Boman BM, Wicha MS, Fields JZ, et al. Symmetric division of cancer stem cells-a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clin Pharmacol Ther. 2007;81(6):893-898.
[44] Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 2006;441(7097): 1068-1074.
[45] Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol. 2008;26(17):2795-1799.
[46] Alison MR, Lim SML, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol. 2011;223(2): 148-162.
[47] Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4): 275-284.
[48] Bernards R, Weinberg RA. Metastasis genes: a progression puzzle. Nature. 2002;418(6900): 823-823.
[49] Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124(6): 1111-1115.
[50] Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009;14(1): 3-9.
[51] Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009;460(7259):1132-1135.
[52] Marión RM, Strati K, Li H, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009;460(7259):1149-1153.
[53] Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009;460(7259):1140-1144.
[54] Utikal J, Polo JM, Stadtfeld M, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009;460(7259):1145-1148.
[55] Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature. 2009;460(7259):1085-1086.
[56] Xu Y. A new role of p53 in maintaining genetic stability in embryonic stem cells. Cell Cycle. 2005;4(3):363-364.
[57] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
[58] Barberi T, Klivenyi P, Calingasan NY, et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol. 2003;21(10):1200-1207.
[59] Lou YJ, Liang XG. Embryonic stem cell application in drug discovery. Acta Pharmacol Sin. 2011;32(2):152-159. |